Sample6
Boston
About Sample6
Sample6 is a synthetic-biology based bacteria diagnostic system capable of enrichment-free detection. Its technology detects as low as 1CFU/ml in just 4 hours. Its proprietary Bioillumination Platform was developed by Professor Tim Lu (MIT) and Dr. Michael Koeris in the lab of Professor James Collins at the Howard Hughes Medical Institute and Boston University. The platform allows for the engineering of bioparticles that target and “light up” specific unwanted bacteria’or specific groups of bacterial species. They couple this capability with highly sensitive sensor technology that detects low levels of pathogens to see results in minutes’right on-site’with no laboratory required. Sample6′s mission is to improve the health and safety of global consumers by building integrated systems that quickly and easily detect harmful and unwanted bacteria. They see applications in food production, retailing, healthcare, and beyond’anywhere humans and bacteria intersect.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $41.7M
- Funding stage: Late Stage Venture
- Last round: Series C (Aug 2016)
- Website: phagediagnostics.com
- Phone: 617-393-7600
Industries & Categories
Biotechnology, Health Diagnostics, Medical, Sensor
Social Profiles
Canonical: https://fsome.com/organization/sample6-217563 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.